Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis

Marco Carbone, Ana Lleo, Richard N. Sandford, Pietro Invernizzi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Genome-wide association studies (GWAS) have revolutionized the search for genetic influences on complex disorders, such as primary biliary cirrhosis (PBC). Recent GWAS have identified many disease-associated genetic variants. These, overall, highlighted the remarkable contribution of key immunological pathways in PBC that may be involved in the initial mechanisms of loss of tolerance and the subsequent inflammatory response and chronic bile duct damage. Results from GWAS have the potential to be translated in biological knowledge and, hopefully, clinical application. There are a number of immune pathways highlighted in GWAS that may have therapeutic implications in PBC and in other autoimmune diseases, such as the anti-interleukin-12/interleukin-23, nuclear factor-kb, tumor necrosis factor, phosphatidylinositol signaling and hedgehog signaling pathways. Further areas in which GWAS findings are leading to clinical applications either in PBC or in other autoimmune conditions, include disease classification, risk prediction and drug development. In this review we outline the possible next steps that may help accelerate progress from genetic studies to the biological knowledge that would guide the development of predictive, preventive, or therapeutic measures in PBC.

Original languageEnglish (US)
Pages (from-to)945-954
Number of pages10
JournalEuropean Journal of Immunology
Volume44
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Biliary Liver Cirrhosis
Genome-Wide Association Study
Interleukin-23
Therapeutics
Inborn Genetic Diseases
Interleukin-12
Phosphatidylinositols
Bile Ducts
Autoimmune Diseases
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations

Keywords

  • Autoimmunity
  • Genetics
  • Liver immunology

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. / Carbone, Marco; Lleo, Ana; Sandford, Richard N.; Invernizzi, Pietro.

In: European Journal of Immunology, Vol. 44, No. 4, 2014, p. 945-954.

Research output: Contribution to journalArticle

Carbone, Marco ; Lleo, Ana ; Sandford, Richard N. ; Invernizzi, Pietro. / Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. In: European Journal of Immunology. 2014 ; Vol. 44, No. 4. pp. 945-954.
@article{25e68413328943159c6be29e5752657b,
title = "Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis",
abstract = "Genome-wide association studies (GWAS) have revolutionized the search for genetic influences on complex disorders, such as primary biliary cirrhosis (PBC). Recent GWAS have identified many disease-associated genetic variants. These, overall, highlighted the remarkable contribution of key immunological pathways in PBC that may be involved in the initial mechanisms of loss of tolerance and the subsequent inflammatory response and chronic bile duct damage. Results from GWAS have the potential to be translated in biological knowledge and, hopefully, clinical application. There are a number of immune pathways highlighted in GWAS that may have therapeutic implications in PBC and in other autoimmune diseases, such as the anti-interleukin-12/interleukin-23, nuclear factor-kb, tumor necrosis factor, phosphatidylinositol signaling and hedgehog signaling pathways. Further areas in which GWAS findings are leading to clinical applications either in PBC or in other autoimmune conditions, include disease classification, risk prediction and drug development. In this review we outline the possible next steps that may help accelerate progress from genetic studies to the biological knowledge that would guide the development of predictive, preventive, or therapeutic measures in PBC.",
keywords = "Autoimmunity, Genetics, Liver immunology",
author = "Marco Carbone and Ana Lleo and Sandford, {Richard N.} and Pietro Invernizzi",
year = "2014",
doi = "10.1002/eji.201344270",
language = "English (US)",
volume = "44",
pages = "945--954",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis

AU - Carbone, Marco

AU - Lleo, Ana

AU - Sandford, Richard N.

AU - Invernizzi, Pietro

PY - 2014

Y1 - 2014

N2 - Genome-wide association studies (GWAS) have revolutionized the search for genetic influences on complex disorders, such as primary biliary cirrhosis (PBC). Recent GWAS have identified many disease-associated genetic variants. These, overall, highlighted the remarkable contribution of key immunological pathways in PBC that may be involved in the initial mechanisms of loss of tolerance and the subsequent inflammatory response and chronic bile duct damage. Results from GWAS have the potential to be translated in biological knowledge and, hopefully, clinical application. There are a number of immune pathways highlighted in GWAS that may have therapeutic implications in PBC and in other autoimmune diseases, such as the anti-interleukin-12/interleukin-23, nuclear factor-kb, tumor necrosis factor, phosphatidylinositol signaling and hedgehog signaling pathways. Further areas in which GWAS findings are leading to clinical applications either in PBC or in other autoimmune conditions, include disease classification, risk prediction and drug development. In this review we outline the possible next steps that may help accelerate progress from genetic studies to the biological knowledge that would guide the development of predictive, preventive, or therapeutic measures in PBC.

AB - Genome-wide association studies (GWAS) have revolutionized the search for genetic influences on complex disorders, such as primary biliary cirrhosis (PBC). Recent GWAS have identified many disease-associated genetic variants. These, overall, highlighted the remarkable contribution of key immunological pathways in PBC that may be involved in the initial mechanisms of loss of tolerance and the subsequent inflammatory response and chronic bile duct damage. Results from GWAS have the potential to be translated in biological knowledge and, hopefully, clinical application. There are a number of immune pathways highlighted in GWAS that may have therapeutic implications in PBC and in other autoimmune diseases, such as the anti-interleukin-12/interleukin-23, nuclear factor-kb, tumor necrosis factor, phosphatidylinositol signaling and hedgehog signaling pathways. Further areas in which GWAS findings are leading to clinical applications either in PBC or in other autoimmune conditions, include disease classification, risk prediction and drug development. In this review we outline the possible next steps that may help accelerate progress from genetic studies to the biological knowledge that would guide the development of predictive, preventive, or therapeutic measures in PBC.

KW - Autoimmunity

KW - Genetics

KW - Liver immunology

UR - http://www.scopus.com/inward/record.url?scp=84898011122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898011122&partnerID=8YFLogxK

U2 - 10.1002/eji.201344270

DO - 10.1002/eji.201344270

M3 - Article

C2 - 24481870

AN - SCOPUS:84898011122

VL - 44

SP - 945

EP - 954

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 4

ER -